Home  »  Markets   »  Summit Therapeutics Inc. (SMMT): These Numbers Sho...

Summit Therapeutics Inc. (SMMT): These Numbers Show Where NASDAQ:SMMT Stock Is Going Next

Summit Therapeutics Inc. (NASDAQ: SMMT) is -2.35% lower on its value in year-to-date trading and has touched a low of $0.66 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SMMT stock was last observed hovering at around $4.46 in the last trading session, with the day’s loss setting it -0.31% off its average median price target of $4.00 for the next 12 months. It is also -3.75% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are -3.75% lower than the price target low of $4.00 for the same period.

Currently trading at $4.15, the stock is -6.04% and 41.09% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.81 million and changing -6.95% at the moment leaves the stock 152.08% off its SMA200. SMMT registered 101.46% gain for a year compared to 6-month gain of 287.85%.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The stock witnessed a 5.60% loss in the last 1 month and extending the period to 3 months gives it a 270.54%, and is -9.59% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.70% over the week and 20.21% over the month.

Summit Therapeutics Inc. (SMMT) has around 105 employees, a market worth around $805.06M and $1.00M in sales. Distance from 52-week low is 528.79% and -28.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-103.50%).

Summit Therapeutics Inc. (SMMT) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Summit Therapeutics Inc. (SMMT) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 1.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Summit Therapeutics Inc. is expected to release its quarterly report on 05/15/2023.The EPS is expected to shrink by -26.70% this year.

Summit Therapeutics Inc. (SMMT) Top Institutional Holders

The shares outstanding are 148.58M, and float is at 34.00M with Short Float at 11.65%.

Summit Therapeutics Inc. (SMMT) Insider Activity

The most recent transaction is an insider purchase by DUGGAN ROBERT W,the company’sChief Executive Officer. SEC filings show that DUGGAN ROBERT W bought 94,849,203 shares of the company’s common stock on Aug 16 at a price of $0.97 per share for a total of $92.0 million. Following the purchase, the insider now owns 162.53 million shares.

Summit Therapeutics Inc. disclosed in a document filed with the SEC on Aug 16 that Zanganeh Maky (Co-CEO & President) bought a total of 5,624,702 shares of the company’s common stock. The trade occurred on Aug 16 and was made at $0.97 per share for $5.46 million. Following the transaction, the insider now directly holds 7.06 million shares of the SMMT stock.

Still, SEC filings show that on Aug 16, Zanganeh Maky (Co-CEO & President) acquired 184,430 shares at an average price of $0.97 for $0.18 million. The insider now directly holds 359,969 shares of Summit Therapeutics Inc. (SMMT).

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts